June 29 (Reuters) – Nuvox Pharma:
HEALTH CANADA ALLOWS COVID-19 PATIENTS WITH RESPIRATORY FAILURE TO BE GIVEN NUVOX PHARMA’S OXYGEN THERAPEUTIC IN PHASE IIA CLINICAL TRIAL
NUVOX PHARMA – RECEIVED “NO OBJECTION LETTER” FROM HEALTH CANADA TO PROCEED WITH PHASE IIA CLINICAL TRIAL OF NANO2 IN COVID-19 SUBJECTS WITH AHRF Source textual issue for Eikon: ]
Our Standards: The Thomson Reuters Belief Rules.
